BNP/CALL/ASTRAZENECA/14000/0.1/20.06.25 Stock

DE000PC836H2

Market Closed - Boerse Frankfurt Warrants 11:20:54 2024-06-14 EDT
1.04 ^EUR	+7.22%

1 month

+16.85%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart BNP/CALL/ASTRAZENECA/14000/0.1/20.06.25

Latest news about ASTRAZENECA PLC

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial	06-16	BU
AstraZeneca : Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial	06-16	PU
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading	06-14	MT
AstraZeneca - Farxiga approved in the US for the treatment of paediatric type-2 diabetes	06-13	AQ

More news

Quotes 5-day view

Date	Price	Change
24-06-14	1.04	+7.22%
24-06-13	0.97	-3.00%
24-06-12	1	+5.26%
24-06-11	0.95	-8.65%
24-06-10	1.04	0.00%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 11:20 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	BNP Paribas
WKN	PC836H
ISIN	DE000PC836H2
Date issued	2024-04-30
Strike	14,000 p
Maturity	2025-06-20 (369 Days)
Parity	10 : 1
Emission price	0.61 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.08 €
Lowest since issue	0.74 €
Spread	0.01 €
Spread %	0.95%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company